Novel Epidermal Growth Factor Receptor Inhibitor Attenuates Angiotensin II-Induced Kidney Fibrosis

Area of Science:

• Nephrology
• Molecular Biology
• Pharmacology

Background:

• Chronic activation of the renin-angiotensin system (RAS) accelerates chronic kidney disease (CKD) progression, primarily through renal fibrosis.
• Angiotensin II (Ang II), a key RAS component, drives fibrotic destruction, but its molecular mechanisms in CKD remain unclear.

Purpose of the Study:

• To investigate the role of epidermal growth factor receptor (EGFR) in Ang II-induced renal fibrosis.
• To explore EGFR inhibition as a potential therapeutic strategy for Ang II-dependent renal deterioration.

Main Methods:

• In vitro studies using Ang II-treated SV40 mesangial cells with EGFR inhibition (small molecules or shRNA).
• Analysis of signaling pathways (Akt, ERK, TGF-β/Smad) and fibrotic markers (CTGF, Collagen IV).
• In vivo validation using a mouse model of Ang II-induced renal fibrosis treated with an EGFR inhibitor.

Main Results:

• EGFR inhibition in vitro suppressed Ang II-induced activation of Akt, ERK, and TGF-β/Smad pathways.
• EGFR inhibition abolished the accumulation of fibrotic markers like connective tissue growth factor and collagen IV.
• In vivo, EGFR small molecule inhibitor attenuated renal fibrosis and kidney dysfunction in mice infused with Ang II.

Conclusions:

• EGFR plays a critical role in Ang II-mediated renal fibrosis and kidney dysfunction.
• EGFR transactivation by Ang II is dependent on c-Src kinase phosphorylation.
• Targeting EGFR represents a promising therapeutic approach for preventing CKD progression.